SCHEMBL18969781

SCHEMBL18969781

CCn1c(/C=C/c2ccccc2)nc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 11/20 1.00
▸ ALDH1A1 P00352 11/20 1.00
▸ SMN1; SMN2 Q16637 10/20 1.00
▸ RAB9A P51151 9/20 1.00
▸ NPC1 O15118 8/20 1.00
▸ GLA P06280 7/20 1.00
▸ GAA P10253 7/20 1.00
▸ HPGD P15428 7/20 1.00
▸ MAPT P10636 5/20 1.00
▸ PKM P14618 3/20 1.00
▸ NFKB1 P19838 3/20 1.00
▸ NFKB2 Q00653 3/20 1.00
▸ RELA Q04206 3/20 1.00
▸ L3MBTL1 Q9Y468 7/20 0.78
▸ TP53 P04637 6/20 0.78
▸ TDP1 Q9NUW8 3/20 0.78
▸ CYP1A2 P05177 1/20 0.78
▸ CYP3A4 P08684 1/20 0.78
▸ CYP2D6 P10635 1/20 0.78
▸ CYP2C19 P33261 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22822637 0.88 SMN1; SMN2 (0.79) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL22822638 0.88 SMN1; SMN2 (1.00) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL29467866 0.88 SMN1; SMN2 (1.00) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL13166604 0.85 SMN1; SMN2 (0.90) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL22822619 0.84 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL22822636 0.83 ALDH1A1 (0.76) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL21749197 0.82 SMN1; SMN2 (0.69) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL21749198 0.82 SMN1; SMN2 (0.69) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL20777209 0.81 SMN1; SMN2 (0.81) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL8551153 0.79 NPC1 (1.00) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395203-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS PLEX PHARMACEUTICALS, INC. 2021-12-23 — — US disclosed
US-20200399219-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS PLEX PHARMACEUTICALS, INC. 2020-12-24 — — US disclosed
WO-2019040463-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS PLEX PHARMACEUTICALS, INC. (US) 2019-02-28 — — WO disclosed
WO-2017100525-A1 SUBSTITUTED BENZIMIDAZOLIUM, PYRIDO-IMIDAZOLIUM, OR PYRAZINO-IMIDAZOLIUM COMPOUNDS AS CHEMOTHERAPEUTICS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399219-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS FKBP2, FKBP1B, FKBP1A KDM4E 4652/4885ALDH1A1 3559/4885SMN1; SMN2 379/4885
US-20210395203-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS FKBP2, FKBP1B, FKBP1A KDM4E 4652/4885ALDH1A1 3559/4885SMN1; SMN2 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback